drugset / Trial / NCT00219843

Intralesional PV-10 Chemoablation of Metastatic Melanoma

NCT00219843

Phase 1 Completed 20 enrolled Provectus Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of metastatic melanoma. This study will also include a preliminary assessment of response of treated and untreated lesions by clinical evaluation at follow-up of 12 to 24 weeks following IL PV-10 treatment.

Timeline

Start
2005-08
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject PV-10 Unknown 10 % Other

Indications